NoviThera has initiated the first efficacy animal studies
Nordicus (OTCQB: NORD) majority-owned subsidiary NoviThera has initiated its first animal efficacy studies for a novel monoclonal antibody targeting a human cathelicidin polypeptide implicated in psoriasis.
Two preclinical mouse programs are underway: intradermal injection models testing antibody efficacy at plaque sites, and development of a humanized genetic mouse that produces the human polypeptide. NoviThera plans toxicity studies in 2027 and first-in-human trials in 2028. The invention is attributed to CEO Allan Wehnert in conjunction with Nordicus.
Nordicus (OTCQB: NORD) la controllata NoviThera, di maggioranza, ha avviato i primi studi di efficacia animale per un nuovo anticorpo monoclonale che mira a un polipeptide umano cathelicidina implicato nella psoriasi.
Due programmi preclinici sui topi sono in corso: modelli di iniezione intradermica che testano l’efficacia dell’anticorpo sui siti delle placche e lo sviluppo di un topo geneticamente umanizzato che produce il polipeptide umano. NoviThera prevede studi di tossicità nel 2027 e primi studi sull’uomo nel 2028. L’invenzione è attribuita al CEO Allan Wehnert in collaborazione con Nordicus.
Nordicus (OTCQB: NORD) la subsidiaria de mayoría NoviThera ha iniciado sus primeros estudios de eficacia animal para un nuevo anticuerpo monoclonal dirigido a un polipéptido humano de catelicidina implicado en la psoriasis.
Dos programas preclínicos en ratones están en curso: modelos de inyección intradérmica que prueban la eficacia del anticuerpo en las placas y el desarrollo de un ratón geneticamente humanizado que produce el polipéptido humano. NoviThera planea estudios de toxicidad en 2027 y ensayos en humanos por primera vez en 2028. La invención se atribuye al CEO Allan Wehnert junto con Nordicus.
Nordicus (OTCQB: NORD) 다수 지분을 보유한 자회사 NoviThera는 건선에 관여하는 인간 카텔리시딘 폴리펩타이드를 표적으로 하는 새로운 단일클론항체에 대한 최초의 동물 효능 연구를 시작했습니다.
두 개의 전임상 쥐 연구가 진행 중입니다: 병변 부위에서 항체의 효능을 검사하는 피부 내 주사 모델과 인간 폴리펩타이드를 생산하는 인간화된 유전적 쥐의 개발. NoviThera는 2027년에 독성 연구를 계획하고 2028년에 인간 대상 1상 임상을 시작할 예정입니다. 발명은 Nordicus와 함께 CEO Allan Wehnert에게 귀속됩니다.
Nordicus (OTCQB : NORD) la filiale majoritaire NoviThera a lancé ses premières études d’efficacité animale pour un nouveau anticorps monoclonal visant un polypeptide humain cathelicidine impliqué dans le psoriasis.
Deux programmes précliniques chez la souris sont en cours: des modèles d’injection intradermique testant l’efficacité de l’anticorps sur les sites des plaques, et le développement d’une souris génétiquement humanisée qui produit le polypeptide humain. NoviThera prévoit des études de toxicité en 2027 et des essais chez l’homme en 2028. L’invention est attribuée au CEO Allan Wehnert conjointement avec Nordicus.
Nordicus (OTCQB: NORD) ist eine Mehrheitsbeteiligung Tochtergesellschaft NoviThera und hat die ersten Tierwirkungsstudien für ein neuartiges monoklonales Antikörper eingeleitet, das auf ein menschliches Cathelicidin-Polypeptid abzielt, das mit Psoriasis in Verbindung gebracht wird.
Zwei präklinische Mausprogramme befinden sich in der Durchführung: intradermale Injektionsmodelle, die die Wirksamkeit des Antikörpers an Plaque-Stellen testen, und die Entwicklung einer humanisierten genetischen Maus, die das humane Polypeptid produziert. NoviThera plant Toxikostudien im 2027 und erste Humanstudien im 2028. Die Erfindung wird dem CEO Allan Wehnert in Zusammenarbeit mit Nordicus zugeschrieben.
Nordicus (OTCQB: NORD) شركة فرعية مملوكة بشكل رئيسي من NoviThera قد باشرت دراسات الفعالية الحيوانية لأول مرة لمضاد أحادي النسيلة يستهدف بوليبتيد بشري من كاثيليسينيد المرتبط بالصدفية.
هناك برنامجان حيويان ما قبل السريرية على الفئران جاريان: نماذج حقن داخل الجلد تختبر فعالية المضاد عند مواقع اللويحات، وتطوير فأر موروث وراثيًا بشريًا ينتج البوليببتيد البشري. تخطط NoviThera لإجراء دراسات سمية في 2027 وتجارب في البشر لأول مرة في 2028. تُنسب الاختراع إلى المدير التنفيذي آلـن وينتورت بالتعاون مع Nordicus.
- Initiation of two preclinical efficacy mouse studies
- Plan for toxicity studies in 2027
- Targeted first-in-human trials in 2028
- Proprietary monoclonal antibody targeting human cathelicidin
- Polypeptide is human-only, requiring engineered humanized mice
- No clinical safety or efficacy data yet; human testing planned in 2028
BEVERLY HILLS, California, Nov. 13, 2025 (GLOBE NEWSWIRE) -- NoviThera ApS (“NoviThera”), a majority owned subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, today announced it has initiated the first efficacy studies on animals.
Psoriasis is an Immune-mediated inflammatory disease that causes keratinocyte hyperproliferation and inflammation. The typical presentation is well-demarcated erythematous plaques with silvery scale on extensor surfaces, scalp, sacral area, nails (pitting, onycholysis). The disorder is typically treated with topical cream, phototherapy and severe cases with interleukin antibodies.
NoviThera is reporting more information about the program. We have established that psoriasis is formed when high concentration of an endogenous polypeptide is present. They are controlling the pathological process, and it is our hypothesis that removal/reduction of this polypeptide will cure and prevent progression of psoriasis.
How does the polypeptide work
The polypeptide is a cathelicidin antimicrobial peptide produced by various cells, including keratinocytes and plays a crucial role in the innate immune response, exhibiting antimicrobial, immunomodulatory and wound-healing properties.
Psoriasis is a chronic inflammatory skin condition characterized by rapid skin cell proliferation and immune dysregulation.
The polypeptide helps defend against pathogens, reducing the risk of infections in psoriatic lesions. It acts at regulating the immune system and has a Pro-inflammatory Role in psoriasis, where it can exacerbate inflammation by promoting the activation of immune cells, such as dendritic cells and T cells. In addition, it regulates the Cytokine Production by stimulating the production of pro-inflammatory cytokines (e.g., IL-17, IL-22), which are pivotal in psoriasis pathogenesis. The overexpression of the polypeptide in psoriatic lesions can attract immune cells, further perpetuating inflammation and skin damage.
The polypeptide binds to self-DNA and self-RNA released from damaged keratinocytes. This protects nucleic acids from degradation and allows them to activate plasmacytoid dendritic cells (pDCs) via Toll-like receptor 9 (TLR9) or TLR7/8. Activated pDCs produce large amounts of type I interferons (especially IFN-α).
IFN-α activates myeloid dendritic cells, which present antigens and release cytokines (IL-12, IL-23). These promote differentiation of Th1 and Th17 cells, leading to secretion of IL-17, IL-22, IFN-γ, TNF-α. This drives keratinocyte hyperproliferation and the psoriatic plaque phenotype.
Ongoing activities
We are currently running two preclinical mouse studies to document biological proof of concept. In the first study we perform intradermal injections at the plaque site and those animals that develop psoriasis will be treated with our proprietary Monoclonal antibody to demonstrate biological efficacy.
In the second study we are developing a humanized genetic mouse that can produce polypeptide. The polypeptide is only made in humans and not in animals. This will allow us to perform more animal studies.
After the studies have been completed, NoviThera plans to test the drug in toxicity studies during 2027 and in patients during 2028.
NoviThera is developing a novel anti Monoclonal anti Body treatment.
The invention was made by Allan Wehnert, CEO of NoviThera in conjunction with Nordicus.
About NoviThera
NoviThera’s mission is to research and develop a novel and unique Monoclonal antibody (MaB) as a novel innovative therapy for the treatment of psoriasis.
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue,” “confident” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition, prospects of being listed on Nasdaq and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For further information, contact:
Investor inquiries:
Nordicus Investor Relations
info@nordicuspartners.com
Media inquiries:
Ulveman & Børsting
kontakt@ulvemanborsting.com
FAQ
What preclinical studies has NoviThera started for NORD on November 13, 2025?
What is NoviThera's planned timeline for toxicity and human trials for NORD?
What therapeutic approach is NoviThera developing under NORD?
Why does NoviThera need a humanized mouse model for the NORD program?
Who is credited with the invention behind NoviThera's NORD therapy?
How will NoviThera test biological efficacy in the initial NORD animal study?
